Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. It holds a majority equity interest in LipoMedix Pharmaceuticals Ltd. (a clinical-stage pharmaceutical company), Barer Institute Inc. (a preclinical cancer metabolism research operation), and a majority interest in Cornerstone Pharmaceuticals, Inc. (a cancer metabolism-based therapeutics company). It holds a majority interest in Rafael Medical Devices, LLC., an orthopedic-focused medical device company, and a majority interest in Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their cannabis offerings enabling them to bring to market predictable versions by utilizing Day Three's pharmaceutical-grade technology and innovation like Unlokt. Its investments include Cyclo Therapeutics Inc. (developing Trappsol Cyclo). It holds a portion of a commercial building in Israel.
BörsenkürzelRFL
Name des UnternehmensRafael Holdings Inc
IPO-datumMar 12, 2018
CEOMr. Howard S. Jonas
Anzahl der mitarbeiter28
WertpapierartOrdinary Share
GeschäftsjahresendeMar 12
Addresse520 Broad Street
StadtNEWARK
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl07120
Telefon12126581450
Websitehttps://rafaelholdings.com
BörsenkürzelRFL
IPO-datumMar 12, 2018
CEOMr. Howard S. Jonas
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten